CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...